People might be interested to view the FDAs own limited conflicts disclosure report related to the members of the
Panel on COVID-19 Treatment Guidelines Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics
9 panel members disclosed connections to Gilead. This same panel approved Gileads Remdesivir as a Covid-19 treatment this approval was later withdrawn.
This FDA disclosure only covers the previous 11 months of conflicts and does not disclose other non financial relationships or those that recently expired
It is worth noting 2 of the CDC / NIH Covid-19 Panels 3 co-chairs have long term links to Gilead which are hard to find and do not need to be declared or disclosed.
One of these Dr Masur speaks regularly at a Gilead sponsored event
Author: Henry Masur, MD
A search for Dr Roy Gulick another co-chair is more problematic his disclosures usually say no relevant financial disclosures to make
However a google search turns up medscape links that need a login to access but can be seen in the google search summary to refer to receiving Gilead research grants, educational fees and consultancy payments
Target Audience and Goal Statement
- Authors: Roy M. Gulick, MD, MPH
This activity is intended for HIV specialists, infectious disease specialists, and other healthcare providers who manage patients with HIV infection.
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Roy M. Gulick, MD, MPH
Associate Professor of Medicine, Weill Medical College of Cornell University; Associate Attending Physician, New York Presbyterian Hospital, New York, New York
: Roy M. Gulick, MD, MPH, has disclosed that he has received research grants from Gilead
, Merck, Panacos, Pfizer, Schering, and Tibotec.
: Dr. Gulick has
also disclosed that he has
served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead
, GlaxoSmithKline, Merck, Monogram, Pfizer, Roche-Trimeris, Tibotec, and Virco, and that he has served as a Data and Safety Monitoring Board Member for Koronis.
Other links state....
Dr Gulick..........has received grants
for educational activities from Gilead
The third co-chair is Dr Clifford Lane has co-authored a postive study on Remdesivir as a Covid-19 treatment
However Dr Lane does not need to declare any indirect connections to Gilead or Remdesivir / Veklury on his CDC disclosures such as co-authoring papers finding in favor of Remdesivir
Further Dr Fauci and Dr Lane published a joint paper which was generally in favor of Remdesivir and against Hydroxychloroquine
Find more information about the financial disclosures of the U.S. Department of Health and Human Services COVID-19 panel roster.
Another non Covid-19 FDA Panel has 16 Gilead associated members, some of whom are on the Covid-19 Panel
This shows how far Gilead is able to extend influence into the FDA
Gilead Sciences, the drugmaker behind the experimental COVID-19 treatment remdesivir, spent more on lobbying Congress and the administration in the first quarter of 2020 than it ever has before, according to federal filings.
The pharmaceutical company spent $2.45 million on lobbying in the first three months of the year, a 32% increase over the first quarter of 2019.
On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.
People may also wish to read the info on GS-441524 as a Covid treatment and Gilead. The FDA says GS-441524 should be studied. Researchers indicate it is a better Covid-19 treatment, even Gileads own research indicates this to be true - but nothing happens.
In May 2020 Cancer researchers from the University of Texas set out in some detail why Gileads drug GS-441524 was superior to Gileads Remdesivir as a Coronavirus treatment. This was based both on animals trials and previous research on GS-441524. In some animals trials GS-441524 was compared...
Dr Aberg features on both FDA Panels above as a Gilead connected person. You can see this data from 2018 going back to 2014 below
ProPublica has compiled the disclosed payments from pharma companies to doctors and other health care providers. Search for your doctor in our interactive database.